Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

Chau Vincent; Madan Ravi A.; Figg William D.

首页> 外文期刊>Cancer biology & therapy >Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

【24h】

Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

机译：转移，抵抗前列腺癌同源重组修复中的缺陷

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objective response rate (ORR), and time to pain progression in patients who harbor alterations inBRCA1, BRCA2, andATM. These are groundbreaking findings - this is the first trial that demonstrates the efficacy of olaparib versus standard therapy in a genomically-selected patient population with metastatic prostate cancer. Although this trial does not demonstrate improvements in overall survival (OS), we believe that this may be an underestimation based on trial-design. Future studies of olaparib are likely to yield further promising results.

机译：None

著录项

来源
《Cancer biology & therapy》 |2020年第12期|共4页
作者
Chau Vincent; Madan Ravi A.; Figg William D.;
展开▼
作者单位

NIH Genitourinary Malignancies Branch Bldg 10 Bethesda MD 20892 USA;

NIH Genitourinary Malignancies Branch Bldg 10 Bethesda MD 20892 USA;

NIH Genitourinary Malignancies Branch Bldg 10 Bethesda MD 20892 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Homologous recombination; DNA repair; metastatic prostate cancer; olaparib;

机译：同源重组;DNA修复;转移前列腺癌;奥拉帕里布;

相似文献

外文文献
中文文献
专利

1. Understanding prostate-speciifc antigen dynamics in monitoring metastatic castration-resistant prostate cancer:implications for clinical practice [J] . Atsushi Mizokami, Kouji Izumi, Hiroyuki Konaka, 亚洲男性学杂志（英文版） . 2017,第002期
2. Clinical activity of abiraterone plus prednisone in docetaxel-na(i)ve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer [J] . Guo-Wen Lin, Gao-Xiang Li, Bo Dai, 亚洲男性学杂志（英文版） . 2019,第002期
3. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer [J] . Yun-Jie Yang, Guo-Wen Lin, Gao-Xiang Li, 亚洲男性学杂志（英文版） . 2018,第002期
4. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer:a real-world retrospective study [J] . Jin-Ge Zhao, Hao Zeng, Jian-Dong Liu, 亚洲男性学杂志（英文版） . 2018,第006期
5. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects [J] . Velho Pedro Isaacsson, Qazi Fahad, Hassan Sayeedul, European urology . 2019,第2期

机译：镭-223在骨转移性阉割抗性前列腺癌中的疗效，没有同源修复基因缺陷
6. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer [J] . Peter H. J. Slootbeek, Marleen L. Duizer, Maarten J. van der Doelen, International Journal of Cancer =: Journal International du Cancer . 2021,第2期

机译：DNA损伤修复缺陷和侵蚀性变异特征对转移阉割抗阉割前列腺癌的反应影响
7. Comment on: 'Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer' by De Vincentis et al [J] . De Vincentis Giuseppe, Frantellizzi Viviana European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2021,第1期

机译：评论：'DNA损伤修复缺陷对镭-223的反应和转移性阉割前列腺癌的整体存活的影响'DE VINCENTIS等
8. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
9. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
10. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors [O] . Daniela Criscuolo, Francesco Morra, Riccardo Giannella, 2019

机译：DNA修复中同源重组缺陷的新型生物标志物的鉴定以预测前列腺癌细胞对PARP抑制剂的敏感性。
11. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer [O] . Vincent Chau, Ravi A. Madan, William D. Figg 2020

机译：转移，抵抗前列腺癌的同源重组修复中的利用缺陷
12. Annotating MYC Status in Treatment-Resistant Metastatic Castration-Resistant Prostate Cancer With Gallium-68 Citrate PET. [R] . Aggarwal, R. 2017

机译：用镓-68柠檬酸盐pET注释治疗抗性转移性去势抵抗前列腺癌中的mYC状态。

Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅